Literature DB >> 9071220

Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats.

H C Hatcher1, J X Ma, J Chao, L Chao, A Ottlecz.   

Abstract

PURPOSE: To determine the involvement of rat kallikrein-binding protein (RKBP) in the development of diabetic retinopathy.
METHODS: Diabetes was induced by streptozotocin (STZ) (55 mg/kg body weight in 0.05 M citrate buffer, pH 4.5) in male Sprague-Dawley rats (150 to 175 g, 6 weeks old) as confirmed by hyperglycemia and reduced body weight. Retinas were dissected from animals at 1, 2, and 4 months of diabetes. The functional activity of RKBP in retinal homogenates was determined by its complex formation with tissue kallikrein. Immunoreactive RKBP levels were measured by enzyme-linked immunosorbent assay. The RKBP messenger RNA (mRNA) levels in the retina were measured by Northern blot analysis using the RKBP complementary DNA probe. The activity of total Na+,K(+)-ATPase was determined by a radioassay. Total protein concentration was determined by a protein assay.
RESULTS: The kallikrein-binding activity was reduced in the retinas of STZ-diabetic rats at 1 (59%), 2 (50%), and 4 (38%) months of diabetes compared to those of age-matched control subjects. Levels of immunoreactive RKBP were significantly lower in the diabetic animals at each time point examined compared to those of control subjects. At 1 and 2 months of diabetes, RKBP levels (nanogram/milligram protein) were decreased significantly to 6.9 +/- 0.7 (n = 8) and 10.6 +/- 1.0 (n = 8), respectively, compared to those of age-matched control subjects (14.1 +/- 0.7, n = 8, P < 0.001, and 14.1 +/- 1.2, n = 8, P < 0.01). At 4 months of diabetes, retinal RKBP levels were lower in both control and diabetic groups, but RKBP levels in diabetic groups were significantly lower (5.8 +/- 0.6, n = 8) than those of the age-matched control subjects (8.4 +/- 0.9, n = 8, P < 0.01). Similarly, Northern blot analysis showed that RKBP mRNA levels were reduced in the retina of each group of STZ-diabetic rats, suggesting that the decrease in RKBP occurred at the level of transcription.
CONCLUSIONS: The results show that STZ-induced diabetic rats have decreased retinal RKBP; moreover, this suggests that RKBP may contribute to diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071220

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 2.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

3.  Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family.

Authors:  Bin Zhang; Jose G Abreu; Kevin Zhou; Ying Chen; Yang Hu; Ti Zhou; Xi He; Jian-xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

4.  Increased serum kallistatin levels in type 1 diabetes patients with vascular complications.

Authors:  Alicia J Jenkins; Jeffrey D McBride; Andrzej S Januszewski; Connie S Karschimkus; Bin Zhang; David N O'Neal; Craig L Nelson; Jasmine S Chung; C Alex Harper; Timothy J Lyons; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-09-22

5.  Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.

Authors:  Bin Zhang; Kevin K Zhou; Jian-xing Ma
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

6.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

7.  Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage.

Authors:  G Gao; C Shao; S X Zhang; A Dudley; J Fant; J-X Ma
Journal:  Diabetologia       Date:  2003-05-13       Impact factor: 10.122

8.  Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression.

Authors:  Bo Shen; Robert S Smith; Yi-Te Hsu; Lee Chao; Julie Chao
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents.

Authors:  Haidong Zhu; Julie Chao; Ishita Kotak; Dehuang Guo; Samip J Parikh; Jigar Bhagatwala; Yutong Dong; Sagar Y Patel; Chris Houk; Lee Chao; Yanbin Dong
Journal:  Metabolism       Date:  2012-11-26       Impact factor: 8.694

10.  SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload.

Authors:  Bin Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.